How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?
Recorded April 24, 2020.
At this time, would you consider pausing therapy—specifically signaling inhibitors and/or monoclonal antibodies—in patients with chronic lymphocytic leukemia?
Recorded April 24, 2020.
During the COVID-19 pandemic, would you still recommend immediate upfront autologous transplant in patients with T-cell non-Hodgkin lymphoma?
Recorded April 21, 2020.
Are you proceeding with front-line autologous transplant in patients with mantle cell lymphoma or delaying it during the COVID-19 pandemic?
Recorded April 21, 2020.
As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible?
Recorded April 24, 2020.
Nancy E. Davidson, MD, of the Seattle Cancer Care Alliance, and a member of The ASCO Post Editorial Board, talks about her experiences in one of the communities hardest hit by coronavirus and offers some practical advice on making changes in treatment and research. Recorded April 7, 2020.
